KIYATEC Selected for University Innovation and Entrepreneurship Startup Showcase on Capitol Hill
Company’s Advanced Ex Vivo 3D Cell Culture Technologies Born Out of Federally-Funded Research at Clemson University
GREENVILLE, S.C.– April 10, 2019 – KIYATEC today announced it was selected to participate in The University Innovation and Entrepreneurship Showcase taking place today on Capitol Hill.
Hosted by the Association of Public and Land-grant Universities (APLU) and the Association of American Universities, the showcase will highlight the important role of federally funded university research in driving high-value entrepreneurship and the U.S. innovation economy for members of Congress, their staff and national economic development and innovation policy leaders.
KIYATEC is dedicated to accurately modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision making and drive drug development. Its 3D-PREDICT clinical study analyzes a patient’s live cancer cells, grown in KIYATEC’s laboratory within a biologically-relevant 3D microenvironment, to determine whether those cells respond to guideline-recommended cancer drugs.
“KIYATEC’s 3D cell culture innovation began with research conducted at Clemson University and we have been dedicated ever since to deliver more accurate predictions of patient response to drugs and biologics,” said Matt Gevaert, Founder and CEO of KIYATEC. “We are honored to be recognized today for our efforts in helping to create a better future for cancer patients.”
Featured congressional and agency speakers at the Showcase include:
- Oklahoma Rep. Frank Lucas, ranking member, House Science, Space and Technology Committee
- Texas Rep. Eddie Bernice Johnson, chairwoman of the House Science, Space and Technology Committee
- Andrei Iancu, undersecretary of commerce for intellectual property and director of the U.S. Patent and Trademark Office
- Dr. Phillip Singerman, associate director for innovation and industry services at the National Institute of Standards and Technology
- Peter McPherson, APLU president
- Mary Sue Coleman, AAU president
“Path-breaking research is fundamental to the mission of public universities,” said APLU President McPherson. “Strong federal investment in university-based research is essential for our nation because that research provides the foundation for the development of new technologies that save lives, make us more secure, improve our quality of life, and power our economy forward. We’re thrilled to highlight some of the best startups sparked out of that investment to demonstrate how university-based research fuels innovation and entrepreneurship across the country. These startups are examples of why 88 percent of voters agree it’s important for the federal government to fund science and technology research. Scientific research spurs economic growth.”
Of the showcase, AAU President Mary Sue Coleman said, “The partnership between the government and American research universities lies at the heart of the U.S. scientific and higher education enterprise. This unique American partnership has empowered entrepreneurs to start companies and entire new industries that have advanced our health, national security, and economy.”
Startups were chosen by a selection committee comprised of innovation experts who considered the level of student engagement in the startup, the strength of the startup technology, and its connection to research. The committee also factored whether the affiliated university had earned APLU’s Innovation & Economic Prosperity University designation, a national recognition for higher education institutions that have demonstrated a substantial and sustainable commitment to promoting economic development.
About KIYATEC, Inc.
KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to therapies before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to accurately predict treatment response prior to beginning treatment.
Lauren Arnold, 781-235-3060